Ï㽶ÊÓƵ

Shane Lloyd
( out of 96 reviews )

Shane Lloyd, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
Salt Lake City
801-581-2396

Sugar House Health Center

Salt Lake City
801-581-2000

  • Shane Lloyd, MD, is an associate professor of radiation oncology at the Ï㽶ÊÓƵ of Utah School of Medicine and Huntsman Cancer Institute. Dr. Lloyd is passionate about providing the best possible care for patients with gastrointestinal, head and neck, and genitourinary cancers.

    Dr. Lloyd is originally from Utah. He received his MD and MHS degrees from Yale Ï㽶ÊÓƵ School of Medicine. He completed an internship at the Ï㽶ÊÓƵ of Utah, and a residency in radiation oncology at Yale New Haven Hospital in New Haven, Connecticut.

    Dr. Lloyd believes in demonstrating and improving care quality through data collection and analysis. He strives to make the best clinical trials available to his patients. Dr. Lloyd has authored numerous peer-reviewed research manuscripts about cancer treatment. He serves as the chair of the Radiological Drug Research Committee (RDRC) and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC).

    Specialties

    Board Certification

    American Board of Radiology (Radiation Oncology)

    Patient Rating

    5.0 /5
    ( out of 96 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 28, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr loud is easy to talk to and seems to care about your concerns

    September 20, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Loyd was courteous and straightforward which is what I like and took the time to listen to me

    July 24, 2024
    HUNTSMAN CANCER CENTER

    He was very kind very much to be able to understand. Everything explained. Everything showed everything on the screen and answered questions. Recommend him to anybody.

    July 20, 2024
    SUGAR HOUSE HEALTH CENTER

    The weekly visits by Dr. Lloyd was very beneficial to me because I was to provide updates to my condition and he answered all questions/concerns I had.

    July 09, 2024
    HUNTSMAN CANCER CENTER

    Dr Lloyd was great. Very patient and even answered my silly questions

    July 04, 2024
    HUNTSMAN CANCER CENTER

    Dr. Loyd and his team took great care of main these stressful treatments. Listened with empathy and discussed care, as well as seemed to genuinely care about me. Thank you!

    June 29, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Lloyd gave me tremendous confidence in my initial treatment for prostate cancer nearly 7 years ago. Since that time we have remained in contact, if only socially. Dr. Lloyd encouraged my latest series of psa tests which brought me to the point of exploring the potential for the return of cancer. Both he and his staff pressed me to return to Huntsman for additional testing which helped determine additional cancer had returned, if only in a small amount. Dr. Lloyd arranged additional radiation to resolve the cancer issue. The process has been relatively simple, easy and without concern. My confidence in Dr. Lloyd and his staff is beyond measure! Our advice to others entering the frightening world of cancer is to most definitely visit with Dr. Lloyd as the first step to a cure.

    June 29, 2024
    HUNTSMAN CANCER CENTER

    Dr. Lloyd is a very kind, compassionate person. Great customer service never rushes the appointment altogether always pleasant to see him.

    June 27, 2024
    HUNTSMAN CANCER CENTER

    Careful, attentive, kind and thorough.

    See More Patient Comments

  • Shane Lloyd, MD, is an associate professor of radiation oncology at the Ï㽶ÊÓƵ of Utah School of Medicine and Huntsman Cancer Institute. Dr. Lloyd is passionate about providing the best possible care for patients with gastrointestinal, head and neck, and genitourinary cancers.

    Dr. Lloyd is originally from Utah. He received his MD and MHS degrees from Yale Ï㽶ÊÓƵ School of Medicine. He completed an internship at the Ï㽶ÊÓƵ of Utah, and a residency in radiation oncology at Yale New Haven Hospital in New Haven, Connecticut.

    Dr. Lloyd believes in demonstrating and improving care quality through data collection and analysis. He strives to make the best clinical trials available to his patients. Dr. Lloyd has authored numerous peer-reviewed research manuscripts about cancer treatment. He serves as the chair of the Radiological Drug Research Committee (RDRC) and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC).

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Primary
    Board Certification
    American Board of Radiology (Radiation Oncology)

    Education history

    Residency Radiation Oncology - Yale-New Haven Hospital Resident
    Internal Medicine - Ï㽶ÊÓƵ of Utah Affiliated Hospitals Intern
    Research Fellow Yale School of Medicine Research Fellow
    Yale School of Medicine M.H.S.
    Professional Medical Medicine - Yale School of Medicine M.D.
    Economics and Zoology - Brigham Young Ï㽶ÊÓƵ B.A.

    Selected Publications

    Journal Article

    1. Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW (2024). Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. Qual Life Res. ()
    2. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Haaland B, Porucznik CA, Gren LH, Sanchez A, Lloyd S, ONeil B, Hashibe M (2023). Mental health outcomes in a population-based cohort of patients with prostate cancer. J Natl Cancer Inst, 116(3), 445-454. ()
    3. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Porucznik CA, Gren LH, Sanchez A, Lloyd S, Haaland B, ONeil B, Hashibe M (2023). Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer. JCO Clin Cancer Inform, 7, e2300083. ()
    4. Koric A, Mark B, Chang CP, Lloyd S, Dodson M, Deshmukh VG, Newman M, Date A, Gren LH, Porucznik CA, Haaland B, Henry NL, Hashibe M (2023). Adverse Health Outcomes Among Rural And Urban Breast Cancer Survivors: A Population-Based Cohort Study. Cancer Epidemiol Biomarkers Prev, 86(102430), 1302-1311. ()
    5. Huang D, Chang CE, Newman M, Deshmukh V, Snyder J, Date A, Galvao C, Lloyd S, Henry NL, ONeil B, Hashibe M (2023). Adverse health outcomes among rural prostate cancer survivors: A population-based study. Cancer Epidemiol, 86, 102430. ()
    6. Nielsen S, ONeil B, Chang CP, Mark B, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Henry NL, Lloyd S, Hashibe M (2023). Determining the association of rurality and cardiovascular disease among prostate cancer survivors. Urol Oncol, 41(10), 429.e15-429.e23. ()
    7. Price RG, Lloyd S, Wang X, Haaland B, Nelson G, Salter B (2023). Adipose Tissue Distribution and Body Mass Index (BMI) Correlation With Daily Image-Guided Radiotherapy (IGRT) Shifts of Abdominal Radiation Therapy Patients. Cureus, 15(6), e40979. ()
    8. Hallemeier CL, Moughan J, Haddock MG, Herskovic AM, Minsky BD, Suntharalingam M, Zeitzer KL, Garg MK, Greenwald BD, Komaki RU, Puckett LL, Kim H, Lloyd S, Bush DA, Kim HE, Lad TE, Meyer JE, Okawara GS, Raben A, Schefter TE, Barker JL Jr, Falkson CI, Videtic GMM, Jacob R, Winter KA, Crane CH (2023). Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials. JAMA Netw Open, 6(4), e238504. ()
    9. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer, 20(6), e453-e459. ()
    10. Rock CB, Hutten RJ, Weil CR, Lloyd S, Kerrigan KC, Cannon RB, Hitchcock YJ (2022). Survival outcomes for patients with T3N0M0 squamous cell carcinoma of the glottis treated with definitive radiation alone versus chemoradiation. Head Neck, 45(2), 431-438. ()
    11. Tao R, Chen Y, Kim S, Ocier K, Lloyd S, Poppe MM, Lee CJ, Glenn MJ, Smith KR, Fraser A, Deshmukh V, Newman MG, Snyder J, Rowe KG, Gaffney DK, Haaland B, Hashibe M (2022). Mental health disorders are more common in patients with Hodgkin lymphoma and may negatively impact overall survival. Cancer, 128(19), 3464-3572. ()
    12. Hutten RJ, Weil CR, Gaffney DK, Kokeny K, Lloyd S, Rogers CR, Suneja G (2022). Racial and Ethnic Health Disparities in Delay to Initiation of Intensity-Modulated Radiotherapy. JCO Oncol Pract, 18(10), e1694-e1703. ()
    13. Mao YS, Gao SG, Li Y, Hao AL, Liu JF, Li XF, Rong TH, Fu JH, Ma JQ, Xu MQ, Zhang RQ, Xiao GM, Fu XN, Chen KN, Mao WM, Liu YY, Liu HX, Zhang ZR, Fang Y, Fu DH, Wei XD, Yuan LG, Muhammad S, Wei WQ, Chiu PW, Lloyd S, Schlottmann F, Meredith K, Pimiento JM, Gao YB, He J (2022). Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501). Ann Transl Med, 10(16), 904. ()
    14. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer, 1-9. ()
    15. Fenlon JB, Hutten RJ, Weil CR, Lloyd S, Cannon DM, Kerrigan K, Cannon RB, Hitchcock YJ (2021). Comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma patients with extranodal extension or positive margins. Head Neck, 44(3), 606-614. ()
    16. Parsons MW, Hutten RJ, Tward A, Khouri A, Peterson J, Morrell G, Lloyd S, Cannon DM, Johnson SB (2021). The Effect of Maximum Tumor Diameter by MRI on Disease Control in Intermediate and High-risk Prostate Cancer Patients Treated With Brachytherapy Boost. Clin Genitourin Cancer, 20(1), e68-e74. ()
    17. Hutten RJ, Weil CR, Gaffney DK, Kokeny K, Lloyd S, Rogers CR, Suneja G (2022). Worsening Racial Disparities in Utilization of Intensity Modulated Radiation Therapy. Adv Radiat Oncol, 7(3), 100887. ()
    18. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson SB (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clin Genitourin Cancer, 19(6), e360-e366. ()
    19. Odell DW, Albrechtsen RD, Sindt JE, Gole R, Brown S, Parsons MW, Paxton AB, Sarkar V, Lloyd S, Brogan SE, Tao R (2021). The Effect of Measured Radiotherapy Dose on Intrathecal Drug Delivery System Function. Neuromodulation, 24(7), 1204-1208. ()
    20. Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R (2020). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol, 28(2), 663-675. ()
    21. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson SB (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. Eur Urol Open Sci, 23, 30-33. ()
    22. Sarkar V, Lloyd S, Paxton A, Dial C, Rassiah P, Szegedi MW, Hitchcock YJ, Salter BJ (2021). Evaluation of the dosimetric impact of changes in shoulder position on target coverage for spine SBRT to metastases in the lower cervical spine region. J Radiosurg SBRT, 7(4), 321-328. ()
    23. Szegedi M, Boehm C, Paxton A, Rassiah-Szegedi P, Sarkar V, Zhao H, Su F, Kokeny KE, Lloyd S, Tward J, Salter BJ (2020). Comparison of transperineal ultrasound image guidance technique to transabdominal technique for prostate radiation therapy. Med Phys, 47(12), 6113-6121. ()
    24. Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5. ()
    25. Wells SM, Boothe D, Ager BJ, Tao R, Gilcrease GW 3rd, Lloyd S (2020). Analysis of Nonsurgical Treatment Options for Metastatic Rectal Cancer. Clin Colorectal Cancer, 19(2), 91-99.e1. ()
    26. Aylward A, Park J, Abdelaziz S, Hunt JP, Buchmann LO, Cannon RB, Rowe K, Snyder J, Deshmukh V, Newman M, Wan Y, Fraser A, Smith K, Lloyd S, Hitchcock Y, Hashibe M, Monroe MM (2020). Individualized prediction of late-onset dysphagia in head and neck cancer survivors. Head Neck, 42(4), 708-718. ()
    27. Gruhl JD, Garrido-Laguna I, Francis SR, Affolter K, Tao R, Lloyd S (2020). The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Cancer Med, 9(5), 1703-1711. ()
    28. Aylward A, Abdelaziz S, Hunt JP, Buchmann LO, Cannon RB, Lloyd S, Hitchcock Y, Hashibe M, Monroe MM (2019). Rates of Dysphagia-Related Diagnoses in Long-Term Survivors of Head and Neck Cancers. Otolaryngol Head Neck Surg, 161(4), 643-651. ()
    29. Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL (2018). Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. J Gastrointest Surg, 23(7), 1401-1413. ()
    30. Cannon RB, Kull AJ, Carpenter PS, Francis S, Buchmann LO, Monroe MM, Lloyd S, Hitchcock YJ, Cannon D, Weis JR, Houlton JJ, Hunt JP (2019). Adjuvant radiation for positive margins in adult head and neck sarcomas is associated with improved survival: Analysis of the National Cancer Database. Head Neck, 41(6), 1873-1879. ()
    31. An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, DSouza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja BS (2018). Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol, 131, 88-92. ()
    32. Coffman A, Torgeson A, Lloyd S (2018). Correlates of Refusal of Surgery in the Treatment of Non-metastatic Pancreatic Adenocarcinoma. Ann Surg Oncol, 26(1), 98-108. ()
    33. Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL (2019). Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. J Gastrointest Oncol, 9(6), 982-988. ()
    34. Sarkar V, Lloyd S, Paxton A, Huang L, Su FC, Tao R, Tward J, Zhao H, Salter B (2019). Daily breathing inconsistency in pancreas SBRT: a 4DCT study. J Gastrointest Oncol, 9(6), 989-995. ()
    35. Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S (2019). Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. J Gastrointest Oncol, 9(6), 1014-1026. ()
    36. Tao R, Ager B, Lloyd S, Torgeson A, Denney M, Gaffney D, Kharofa J, Lin SH, Koong AC, Anzai Y, Hoffman JM (2019). Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. J Gastrointest Oncol, 9(6), 1044-1053. ()
    37. Orton A, Boothe D, Evans D, Lloyd S, Monroe MM, Jensen R, Shrieve DC, Hitchcock YJ (2017). Esthesioneuroblastoma: A Patterns-of-Care and Outcomes Analysis of the National Cancer Database. Neurosurgery, 83(5), 940-947. ()
    38. Torrecillas V, Shepherd HM, Francis S, Buchmann LO, Monroe MM, Lloyd S, Cannon D, Hitchcock YJ, Weis JR, Hunt JP, Houlton JJ, Cannon RB (2018). Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. Oral Oncol, 85, 1-7. ()
    39. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386. ()
    40. Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S (2018). Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open, 3(1), e000282. ()
    41. Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao R (2017). Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Ann Surg Oncol, 24(13), 4001-4008. ()
    42. Francis SR, Orton A, Thorpe C, Stoddard G, Lloyd S, Anker CJ (2017). Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer. Int J Radiat Oncol Biol Phys, 99(4), 884-894. ()
    43. Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, Cannon GM (2017). Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer, 123(19), 3816-3824. ()
    44. Gan M, Boothe D, Neklason DW, Samadder NJ, Frandsen J, Keener MB, Lloyd S (2017). Outcomes and complications of radiation therapy in patients with familial adenomatous polyposis. J Gastrointest Oncol, 8(4), 643-649. ()
    45. Jairam V, Yu JB, Aneja S, Wilson LD, Lloyd S (2014). Differences in Funding Sources of Phase III Oncology Clinical Trials by Treatment Modality and Cancer Type. Am J Clin Oncol, 40(3), 312-317. ()
    46. Sowder JC, Cannon RB, Buchmann LO, Hunt JP, Hitchcock Y, Lloyd S, Grossmann KF, Monroe MM (2017). Treatment-related determinants of survival in early-stage (T1-2N0M0) oral cavity cancer: A population-based study. Head Neck, 39(5), 876-880. ()
    47. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, DAmico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ (3/21/17). ACR Appropriateness Criteria® External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer, Part II of II. Adv Radiat Oncol, 2(3), 437-54.
    48. Monroe MM, Buchmann LO, Hunt JP, Hitchcock YJ, Lloyd S, Hashibe M (2017). The Benefit of Adjuvant Radiation in Surgically-Treated T1-2 N1 Oropharyngeal Squamous Cell Carcinoma. Laryngoscope Investig Otolaryngol, 2(2), 57-62. ()
    49. McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, DAmico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ (2017). ACR Appropriateness Criteria(R) Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol, 40(1), 1-10. ()
    50. Lloyd S, Alektiar KM, Nag S, Huang YJ, Deufel CL, Mourtada F, Gaffney DK (2017). Intraoperative high-dose-rate brachytherapy: An American Brachytherapy Society consensus report. Brachytherapy, 16(3), 446-465. ()
    51. Cannon RB, Sowder JC, Buchmann LO, Hunt JP, Hitchcock YJ, Lloyd S, Grossman KF, Monroe MM (2017). Increasing use of nonsurgical therapy in advanced-stage oral cavity cancer: A population-based study. Head Neck, 39(1), 82-91. ()
    52. Davis BJ, Taira AV, Nguyen PL, Assimos DG, DAmico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N (2016). ACR appropriateness criteria permanent source brachytherapy for prostate cancer.LID - S1538-4721(16)30558-X [pii]LID - 10.1016/j.brachy.2016.10.002 [doi]. Brachytherapy. ()
    53. Coffman A, Boothe D, Frandsen J, Lloyd S (11/16/16). Correlates and trends of IMRT use in locally advanced rectal cancer. doi:10.1007/s13566-016-0285-0. J Radiat Oncol, 5(4), 427-35.
    54. Ganesan K, Lloyd S, Sarkar V (2016). Discovering Related Clinical Concepts Using Large Amounts of Clinical Notes. Biomed Eng Comput Biol, 7(Suppl 2), 27-33. ()
    55. Boothe D, Hopkins Z, Frandsen J, Lloyd S (2016). Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma. J Gastrointest Oncol, 7(4), 580-7. ()
    56. Lloyd S, Dosoretz AP, Yu JB, Evans SB, Decker RH (2016). Academic and Resident Radiation Oncologists' Attitudes and Intentions Regarding Radiation Therapy near the End of Life. Am J Clin Oncol, 39(1), 85-9. ()
    57. Odei BC, Boothe D, Lloyd S, Gaffney DK (2016). A comprehensive analysis of brachytherapy clinical trials over the past 15 years. Brachytherapy, 15(6), 679-686. ()
    58. Orton A, Boothe D, Gan M, Monroe MM, Hitchcock YJ, Lloyd S (2016). The "decay" of brachytherapy use in tumors of the oral cavity: A population-based patterns of care and outcomes analysis from 1973 to 2012. Brachytherapy, 15(6), 851-858. ()
    59. Lloyd S, Chung DH, Colaco RJ, Goodrich I, Cardinale FS (10/19/15). The Effect of Dose and Other Parameters on Outcomes in CyberKnife Stereotactic Radiosurgery for Trigeminal Neuralgia. J Radiat Oncol, 4(4), 387-394.
    60. Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd S (2015). Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol, 6(5), 516-23. ()
    61. Husain ZA, Lloyd S, Shah C, Wilson LD, Koshy M, Mahmood U (2015). Changes in brachytherapy-based APBI patient selection immediately before and after publication of the ASTRO consensus statement. Brachytherapy, 14(4), 490-5. ()
    62. Gustafson GS, Nguyen PL, Assimos DG, DAmico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ (2014). ACR appropriateness Criteria(R) Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park), 28(12), 1125-30, 1132-6. ()
    63. Lloyd S, Chang BW (2014). Current strategies in chemoradiation for esophageal cancer. J Gastrointest Oncol, 5(3), 156-65. ()
    64. Lloyd S, Chang BW (2013). New possibilities and potential benefits for local control in locally recurrent pancreatic cancer. J Gastrointest Oncol, 4(4), 340-2. ()
    65. Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD (2013). Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. J Am Acad Dermatol, 69(4), 537-43. ()
    66. Lloyd S, Buscariollo DL, Gross CP, Makarov DV, Yu JB (2013). Determinants of enrollment in cancer clinical trials: the relationship between the current state of knowledge, societal disease burden, and randomized clinical trial enrollment. J Natl Compr Canc Netw, 11(8), 928-36. ()
    67. Lloyd S, Decker RH (2013). Conference Scene: Notable Trial Results in Radiation Therapy for Lung Cancer at the ASCO Annual Meeting. Lung Cancer Manag, 2(4), 271-4.
    68. Lloyd S, Chang BW (2013). A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. J Gastrointest Oncol, 4(2), 123-30. ()
    69. Lloyd S, Decker RH, Evans SB (2013). Bone scan findings of chest wall pain syndrome after stereotactic body radiation therapy: implications for the pathophysiology of the syndrome. J Thorac Dis, 5(2), E41-4. ()
    70. Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S (2013). A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer. Int J Radiat Oncol Biol Phys, 85(1), 40-6. ()
    71. Lloyd S, Yu JB, Wilson LD, Judson BL, Decker RH (2012). The prognostic importance of midline involvement in oral tongue cancer. Am J Clin Oncol, 35(5), 468-73. ()
    72. Lloyd S, Park HS, Decker RH, Wilson LD, Yu JB (2012). Using the Surveillance, Epidemiology, and End Results database to investigate rare cancers, second malignancies, and trends in epidemiology, treatment, and outcomes. Curr Probl Cancer, 36(4), 191-9. ()
    73. Lloyd S, Park HS, Wilson LD, Decker RH, Yu JB (2012). Prediction models, nomograms, and staging validation with the Surveillance, Epidemiology, and End Results database: using Surveillance, Epidemiology and End Results (SEER) program to create prediction models. Curr Probl Cancer, 36(4), 200-7. ()
    74. Park HS, Lloyd S, Decker RH, Wilson LD, Yu JB (2012). Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance. Curr Probl Cancer, 36(4), 183-90. ()
    75. Yu JB, Lloyd S, Decker RH, Wilson LD, Park HS (2012). Comparative Effectiveness Research and the Surveillance, Epidemiology, and End Results database: what is Comparative Effectiveness Research (CER) and why is it important? Curr Probl Cancer, 36(4), 208-15. ()
    76. Park HS, Lloyd S, Decker RH, Wilson LD, Yu JB (2012). Limitations and biases of the Surveillance, Epidemiology, and End Results database. Curr Probl Cancer, 36(4), 216-24. ()
    77. Lloyd S, Yu JB, Wilson LD, Decker RH (2011). Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol, 34(1), 76-81. ()
    78. Lloyd S, Yu JB, Ross DA, Wilson LD, Decker RH (2010). A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. Int J Radiat Oncol Biol Phys, 76(1), 169-75. ()

    Review

    1. Valle LF, Jiang T, Rosenbloom A, Zaorsky NG, Hwang C, Solanki A, Dickstein D, Mitin T, Schroeder T, Potters L, Lloyd S, Showalter T, Bagshaw HP, Jeffrey Karnes R, Hoffman KE, Nguyen PL, Kishan AU (2024). American Radium Society Appropriate Use Criteria for the Workup and Treatment of Local Intraprostatic Recurrence of Prostate Cancer Following Definitive Radiotherapy. [Review]. Eur Urol Oncol. ()
    2. Zhao P, Jin R, Zhao B, Han L, Chen W, Hao N, Cui Y, Madan A, Awosika J, Lloyd S, Zhang Y (2024). The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review. [Review]. J Gastrointest Oncol, 15(1), 514-528. ()
    3. Dinh TT, Mitin T, Bagshaw HP, Hoffman KE, Hwang C, Jeffrey Karnes R, Kishan AU, Liauw SL, Lloyd S, Potters L, Showalter TN, Taira AV, Vapiwala N, Zaorsky NG, DAmico AV, Nguyen PL, Davis BJ (2020). Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. [Review]. Int J Radiat Oncol Biol Phys, 109(4), 953-963. ()
    4. Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S (2019). Large database utilization in health outcomes research in pancreatic cancer: an update. [Review]. J Gastrointest Oncol, 9(6), 996-1004. ()

    Conference Proceedings

    1. Gan M, Boothe D, Neklason DW, Samadder NJ, Frandsen J, Keener MB, Lloyd S (11/30/16). Outcomes and Complications of Radiation Therapy in Patients with Familial Adenomatous Polyposis. Radiological Society of North America, Chicago, Illinois.

    Editorial

    1. Lloyd S (2019). Pancreas cancer, careful improvements and human connections. J Gastrointest Oncol, 9(6), 979-981. ()